Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Retatrutide history: 2022 to today

Retatrutide moved from a 2022 discovery paper to Phase 3 obesity results in four years, but it remains investigational and unapproved.

Why we wrote this. Retatrutide moved quickly from a code name to Phase 3 headlines. A dated timeline shows which claims are published and which remain topline.

In this article (8 sections)
  1. 1. 2022: the triple agonist is published
  2. 2. 2023: Phase 2 obesity results arrive
  3. 3. 2023: diabetes data broaden the case
  4. 4. 2023: the TRIUMPH programme begins
  5. 5. 2024: outcomes research starts
  6. 6. 2026: the first late-stage obesity topline
  7. Where retatrutide stands today
  8. What we do not yet know

Retatrutide history is short because the molecule is still experimental. Lilly first published LY3437943 in 2022, moved through two Phase 2 programmes in 2023 and then opened a large Phase 3 portfolio. In May 2026 the sponsor reported the first late-stage general-obesity result. As of 26 October 2026, retatrutide remains unapproved. There is no authorised brand or ordinary prescription route.

1. 2022: the triple agonist is published

The first major publication used the development code LY3437943. Lilly scientists described one peptide engineered to activate three receptors: GIP, GLP-1 and glucagon. Laboratory testing found balanced activity at the glucagon and GLP-1 receptors, with greater activity at the GIP receptor. In mice with obesity, adding glucagon-receptor activity increased energy expenditure on top of the calorie-intake reduction linked to the GIP and GLP-1 arms[1].

The same paper included an early human study. Its pharmacokinetic profile, meaning how the body handles the molecule over time, supported once-weekly study administration. A body-weight reduction persisted to day 43 after one administration[1]. This was proof of concept, not evidence for an approved treatment. The authors were Lilly employees and stockholders, a relevant conflict when reading an origin paper from the molecule's developer.

2. 2023: Phase 2 obesity results arrive

The obesity study enrolled 338 adults and compared several once-weekly retatrutide groups with placebo for 48 weeks. At week 48, mean body-weight change ranged from a reduction of 8.7% in the 1 mg group to 24.2% in the 12 mg group, compared with 2.1% on placebo. In the 12 mg group, 83% of participants lost at least 15% of baseline weight[2]. Those figures turned an unfamiliar code into a closely watched obesity drug candidate.

The trial also established an early safety pattern. Gastrointestinal events were the most common, increased with dose and were mostly mild or moderate. A lower starting dose partly reduced those early events. Heart rate increased in a dose-dependent pattern, peaked around week 24 and then declined[2]. The result justified larger trials; it did not settle long-term safety.

3. 2023: diabetes data broaden the case

A separate Phase 2 trial enrolled 281 adults with type 2 diabetes. It compared retatrutide with placebo and dulaglutide, an established GLP-1 receptor agonist, over 36 weeks. At week 24, the larger retatrutide groups reduced HbA1c, a marker of average blood glucose, by roughly 1.9 to 2.0 percentage points. At week 36, mean weight reduction was about 16% to 17% in those groups[3].

This study helped Lilly choose doses for Phase 3. It also clarified the comparison with tirzepatide: tirzepatide activates GIP and GLP-1 receptors, while retatrutide adds glucagon-receptor activity. The extra target is the defining design choice, but the Phase 2 programmes cannot tell us by themselves how much each receptor contributed in people.

4. 2023: the TRIUMPH programme begins

Lilly opened a Phase 3 programme under the TRIUMPH name. TRIUMPH-1 began in July 2023 and enrolled 2,335 participants without type 2 diabetes who had obesity or overweight. Its master protocol included the general population plus knee-osteoarthritis and obstructive-sleep-apnoea subsets. The registry lists placebo-controlled body-weight change at week 80 among its primary outcomes[4].

Other TRIUMPH studies asked different questions, including obesity with established cardiovascular disease and a direct comparison with tirzepatide. This matters because a programme is not one trial repeated at larger scale. Each population and endpoint answers a narrower question.

5. 2024: outcomes research starts

TRIUMPH-Outcomes began in April 2024. The registry plans to enrol about 10,000 adults with obesity plus atherosclerotic cardiovascular disease or chronic kidney disease. Its primary endpoints track major cardiovascular events and worsening kidney outcomes, not just changes in body weight. The study is active but no longer recruiting, with estimated completion in February 2029[5].

That long timetable explains why striking weight-loss results and hard health outcomes must remain separate. A scale reading can change within months. Showing whether a treatment prevents heart attacks, strokes or kidney failure takes a larger group and more time.

6. 2026: the first late-stage obesity topline

On 21 May 2026, Lilly reported topline TRIUMPH-1 results rather than a peer-reviewed paper. The sponsor said the 12 mg group lost an average 28.3% of body weight at 80 weeks, compared with 2.2% on placebo. It also reported averages of 25.9% for 9 mg and 19.0% for 4 mg[6]. The ClinicalTrials.gov record now lists the study as completed[4].

Topline means the sponsor has announced selected results before a full journal report exposes the complete methods and analyses to peer review. The figures are an important milestone, but they should still be labelled as sponsor-reported. They are not an approval decision.

Where retatrutide stands today

The FDA says retatrutide is not a component of an FDA-approved drug, has not been found safe and effective for any condition and cannot be used in compounding under US federal law[7]. The US retatrutide regulation page explains what that means for products already sold online under the name.

What happens next depends on full Phase 3 reporting, regulatory submissions and agency review. The cardiovascular and kidney outcomes study extends the evidence timeline to 2029. Until regulators decide otherwise, retatrutide remains a trial medicine rather than a consumer product.

What we do not yet know

No public approval review has yet established a final indication, labelled dose, contraindication set or commercial name. Full peer-reviewed TRIUMPH-1 results were not used for this timeline because the May 2026 source is a sponsor topline release. We also do not have completed cardiovascular or kidney outcomes. Those gaps are not footnotes to the history. They define the stage of development retatrutide has reached.

Frequently asked

When was retatrutide discovered?

Lilly's first major publication on LY3437943 appeared online in August 2022. It described the peptide's three-receptor design, preclinical experiments and early human proof of concept.

When did retatrutide enter Phase 3?

The TRIUMPH Phase 3 programme began in 2023. TRIUMPH-1, the large obesity study without type 2 diabetes, started in July 2023 and is now listed as completed.

Has retatrutide been approved?

No. As of 26 October 2026, retatrutide remains investigational. The FDA says it has not been found safe and effective for any condition and cannot be used in compounding under federal law.

What is the next major retatrutide milestone?

Full reporting and regulatory review of the Phase 3 programme are the near-term milestones. TRIUMPH-Outcomes, which measures cardiovascular and kidney events, is estimated to continue until February 2029.

Sources

  1. [1]Coskun et al. (2022): LY3437943 from discovery to clinical proof of concept (PMID 35985340)Tier 1 · primary↩
  2. [2]Jastreboff et al. (2023): Phase 2 retatrutide obesity trial (PMID 37366315)Tier 1 · primary↩
  3. [3]Rosenstock et al. (2023): Phase 2 retatrutide type 2 diabetes trial (PMID 37385280)Tier 1 · primary↩
  4. [4]ClinicalTrials.gov: TRIUMPH-1 registry record (NCT05929066)Tier 1 · primary↩
  5. [5]ClinicalTrials.gov: TRIUMPH-Outcomes registry record (NCT06383390)Tier 1 · primary↩
  6. [6]Scientific American (21 May 2026): sponsor-reported TRIUMPH-1 retatrutide resultsTier 2 · expert↩
  7. [7]FDA: concerns with unapproved GLP-1 drugs, including retatrutideTier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars